Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study - the Caravaggio study.

Trial Profile

Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study - the Caravaggio study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Apixaban (Primary) ; Dalteparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Caravaggio
  • Most Recent Events

    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top